养心定悸胶囊联合伊伐布雷定对中年冠心病患者心肌梗死术后不良事件、住院时间及生活质量的影响

Effects of Yangxindingji capsule combined with ivabradine on the incidence of adverse events,hospitalization time and life quality of middle-aged patients with coronary heart disease after emergency PCI

目的探究养心定悸胶囊对中年冠心病患者住院期间不良事件发生情况、住院时间、生活质量的影响。方法将2018年1~12月心脏内科就诊并且接受住院治疗的中年冠心病患者355例作为研究对象,均经过急诊PCI治疗后随机分为试验组和对照组。在常规治疗的基础上,对照组使用伊伐布雷定治疗,试验组使用伊伐布雷定联合养心定悸胶囊联合疗法,比较2组患者住院期间不良事件发生情况、住院时间、生活质量、复查依从性及护理满意度情况。结果试验组患者心绞痛发作次数[(6.79±1.55)次/周],明显低于对照组[(11.08±2.79)次/周];试验组住院期间发作持续时长(2.53±0.41)min,明显低于对照组(4.29±1.06)min(P<0.05);试验组住院时间(8.55±1.65)d,明显低于对照组(10.29±2.03)d(P<0.05)。试验组患者生活质量评分(89.75±8.62)分,明显高于对照组[(81.78±7.57)分](P<0.05);试验组患者按照医嘱规律复查85.88%,高于对照组(67.42%)(P<0.05);试验组患者住院满意度评分(92.66±4.07)分,明显高于对照组[(85.48±6.53)分](P<0.05);试验组临床医生的自身成就满意度评分[(95.76±5.33)分],明显高于对照组[(87.59±7.09)分](P<0.05)。结论对中年冠心病患者使用伊伐布雷定联合养心定悸胶囊联合疗法能够有效降低患者心绞痛发作次数、发作时持续时长、减少患者住院时间、提高生活质量,具有一定的临床推广价值。

Objective To investigate the effects of Yangxindingji capsule combined with ivabradine on the incidence of adverse events,hospitalization time and life quality of middle-aged patients with coronary heart disease after emergency PCI.Methods A total of 355 middle-aged patients with coronary heart disease who underwnet emergency PCIin our hospital form January 2018 to December 2018 were enrolled in the stdy,who were randomly divided into experimental group and control group after emergency PCI.On the basis of conventional treatment,the patients in control group were treated by ivabradine,however,the patients in experimental group were treated by ivabradine combined with Yangxindingji capsule.The incidence of adverse events,hospitalization time,life quality of patients as well as the rechecking compliance and satisfaction degree of patients were observed and compared between the two groups.Results The frequency of angina attacks in experimental group was(6.79±1.55)times/week,which was significantly lower than that[(11.08±2.79)times/week]in control group,and the duration of the attack in experimental group during hospitalization was(2.53±0.41)min,which was significantly lower than that[(4.29±1.06)min]in control group.The hospital stay in experimental group was(8.55±1.65)d,which was significantly lower than that[(10.29±2.03)d]in control group.The life quality scores in experimental group were[89.75±8.62 points],which were significantly higher than those[(81.78±7.57)points]in control group,and the proportion of patients who received rechecking according to the medical order in experimental group was 85.88%,which was significantly higher than that(67.42%)in control group(P<0.05).Moreover the hospitalization satisfaction degree scores in experimental group were(92.66±4.07)points,which were significantly higher than those[(85.48±6.53)points]in control group,and the self-satisfaction satisfaction scores of clinical doctors were 95.76±5.33 points,which were significantly higher than those[(87.59±7.09)points]in control group(P<0.05).Conclusion The combination aplication of ivabradine and Yangxindingji capsule in treatment of coronary heart disease in middle-aged patients can effectively reduce the frequency of angina attacks,the duration of attacks,reduce the length of hospital stay,improve the life quality of patients,therefor,it is worthy of clinical promotion.